Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 607 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 28
States / cities: Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Revefenacin, Placebo, Formoterol; Drug
Lead sponsor: Mylan Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 12
States / cities: Miami, Florida • Orlando, Florida • Sarasota, Florida + 9 more

Conditions: Respiratory Syncytial Viruses, Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine, HZ/su vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 530 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 11
States / cities: Daphne, Alabama • Tempe, Arizona • Corte Madera, California + 8 more

Conditions: Hepatitis C
Interventions: BMS-650032, BMS-790052; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Atrial Fibrillation, Stroke
Interventions: Catheter Ablation, Market-approved AVNB, OAC and AAD; Device · Drug
Lead sponsor: Kansas City Heart Rhythm Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 7
States / cities: Overland Park, Kansas • Independence, Missouri • Kansas City, Missouri

Conditions: Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions: Prevnar, Pneumovax; Biological
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Not listed
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fall Patients, Fall Injury
Interventions: Fall prevention algorithm, Inspiren camera visualization; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5,350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Tiotropium Bromide, Fluticasone Propionate/Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 99 Years
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 35
States / cities: Riverside, California • Fort Collins, Colorado • Clearwater, Florida + 31 more

Conditions: Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
Interventions: MEK162, AMG 479; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Salt Lake City, Utah

Conditions: Acne Vulgaris
Interventions: Adapalene/Benzoyl Peroxide, Adapalene, Benzoyl Peroxide, Topical Gel Vehicle; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 12 Years and older
Enrollment: 1,670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 33
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Fresno, California + 30 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CGM + Family Behavioral Intervention, Standard CGM; Behavioral · Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 2 Years to 7 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Migraines, Bleeding, Spotting
Interventions: frovatriptan, placebo; Drug
Lead sponsor: Scott and White Hospital & Clinic; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 560 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 102
States / cities: Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more

Conditions: Chronic Migraine, Behavioral Treatment, Biofeedback, Virtual Reality, Medication Overuse Headache
Interventions: Combined biofeedback-virtual reality device; Device
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Malignancies, Metastatic Cancer
Interventions: INCAGN01876, Epacadostat, Pembrolizumab; Drug
Lead sponsor: Incyte Biosciences International Sàrl; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Hackensack, New Jersey

Conditions: Asthma
Interventions: BGF MDI 320/28.8/9.6 μg, BGF MDI 320/14.4/9.6 μg, BFF MDI 320/9.6 μg, BFF pMDI 320/9 μg; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 2,187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 88
States / cities: Chandler, Arizona • Tempe, Arizona • Tucson, Arizona + 78 more

Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions: GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Weeks to 15 Months
Enrollment: 756 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 27
States / cities: Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more

Conditions: Type 2 Diabetes
Interventions: Intensive lifestyle interventions (ILIs); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dunwoody, Georgia

Conditions: Disability
Interventions: Ohio RETAIN; Other
Lead sponsor: Mathematica Policy Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 4,525 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Early Breast Cancer
Interventions: Ribociclib, Letrozole, Ansastrozole, Goserelin, Leuprolide, Exemestane; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 79
States / cities: Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 69 more

Conditions: Diabetic Neuropathy
Interventions: Exercise; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Facial Pain
Interventions: SinuSonic, Sham Device; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Cancer
Interventions: TTM Tailored, Motivational Enhancement Therapy, Integrated Treatment; Behavioral
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years and older
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Kingston, Rhode Island

Conditions: HIV-1, HIV Infections, Acquired Immunodeficiency Syndrome
Interventions: E/C/F/TAF, DRV, Baseline DRV- containing ARV regimen; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 56
States / cities: Phoenix, Arizona • Beverly Hills, California • Hayward, California + 43 more

Search by objective public record fields.

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD

A Study on Safety and Immune Response of Investigational RSV OA Vaccine in Combination With Herpes Zoster Vaccine in Healthy Adults

Drug-Drug Interaction Study in Healthy Subjects

Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control

Humoral Determinants of Immunity to Pneumococcal Infection

Predictive Analytics and Computer Visualization Enhances Patient Safety to Prevent Falls

A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

Strategies to Enhance New CGM Use in Early Childhood (SENCE)

Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

Biofeedback-VR for Treatment of Chronic Migraine

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (LOGOS)

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

Better Together Study

Ohio RETAIN Impact Evaluation

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

Exercise-facilitated Neurorehabilitation in Diabetic Neuropathy

Treatment of Sinus Headache Using a Novel Device That Combines Acoustic Vibration With Oscillating Expiratory Pressure

Comparing Population Cessation Services

Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults